The therapeutic potential of the cannabinoids in neuroprotection
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
After thousands of years of interest the last few decades have seen a huge increase in our knowledge of the cannabinoids and their mode of action. Their potential as medical therapeutics has long been known. However, very real concerns over their safety and efficacy have lead to caution and suspicion when applying the legislature of modern medicine to these compounds. The ability of this diverse family of compounds to modulate neurotransmission and act as anti-inflammatory and antioxidative agents has prompted researchers to investigate their potential as neuroprotective agents. Indeed, various cannabinoids rescue dying neurones in experimental forms of acute neuronal injury, such as cerebral ischaemia and traumatic brain injury. Cannabinoids also provide symptomatic relief in experimental models of chronic neurodegenerative diseases, such as multiple sclerosis and Huntington's disease. This preclinical evidence has provided the impetus for the launch of a number of clinical trials in various conditions of neurodegeneration and neuronal injury using compounds derived from the cannabis plant. Our understanding of cannabinoid neurobiology, however, must improve if we are to effectively exploit this system and take advantage of the numerous characteristics that make this group of compounds potential neuroprotective agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“The CB1 receptor is expressed predominantly in the CNS with high levels of receptor expression found in brain areas such as cortex, striatum, hippocampus, amygdala [10-13] and in the spinal cord [14].”
BackgroundHerkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“The CB1 receptor is expressed predominantly in the CNS with high levels of receptor expression found in brain areas such as cortex, striatum, hippocampus, amygdala [10-13] and in the spinal cord [14].”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · cited 1×
“HU211 (dexanabinol) protects against oxidative stress in neuronal cultures caused by sodium nitroprusside [40], and cannabidiol and delta-9 THC protect rat primary cortical neuronal cultures from NMDA (N-methyl D-aspartate) neurotoxicity via an antioxidative mechanism [41].”
BackgroundThe Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349 · cited 1×
“The cannabinoid system may still hold some hope to the Parkinsonian patient however, as a recent pilot clinical study indicated that the cannabinoid agonist nabilone significantly reduces levadopa-induced dyskinesias in Parkinson’s disease patients [80].”
BackgroundCannabinoid CB1 Receptor Expression in Rat Spinal Cord
Farquhar-Smith, W. P., Egertová, M., Bradbury, E. J., McMahon, S. B., Rice, A. S. C., & Elphick, M. R. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0844 · Cited by 268
Sacerdote, P., Massi, P., Panerai, A. E., & Parolaro, D. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00307-6 · Cited by 124 · cited 1×
“with the CB2 receptor [36] whilst, conversely, it inhibits chemotaxis in macrophages [37].”
Background
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…sclerosis, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and Alzheimer’s disease (reviewed in Glass, 2001; Mechoulam et al., 2002a,b; Grundy, 2002; Croxford, 2003; Drysdale PACHER et al. Page 21 Pharmacol Rev. Author manuscript; available in PMC 2008 February 13.”
BackgroundSVIZENSKA, I., DUBOVY, P., & SULCOVA, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 457
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320
Metadata
- Authors
- Grundy, R. I.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2002-10
- Volume
- 11
- Issue
- 10
- Pages
- 1365-1374
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2015987706
- Cited by
- 72
- References
- 8
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The therapeutic potential of the cannabinoids in neuroprotection. https://app.cochat.ai/papers/10.1517/13543784.11.10.1365
- The paper
- Grundy, R. I. (2002). The therapeutic potential of the cannabinoids in neuroprotection. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.11.10.1365
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.